Palvella Therapeutics (PVLA)
NASDAQ:PVLA
Top Page
Palvella Therapeutics
(NASDAQ:PVLA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$78.00
▼(-35.21% Downside)
Action:ReiteratedDate:01/30/26
The score is held down primarily by weak financial performance (no current revenue, ongoing losses, and persistent cash burn) and bearish technical signals. Offsetting this, corporate events are notably positive with encouraging Phase 2 data and clear near-term clinical/regulatory catalysts, but this does not fully overcome the current fundamentals and trend.
Positive Factors
Conservative balance sheet
Zero reported debt and materially improved equity provide durable financial flexibility for a clinical‑stage biotech. This reduces near‑term refinancing pressure, supports milestone funding for trials, and lowers bankruptcy risk compared with highly levered peers over the next 2–6 months.
Negative Factors
No recurring revenue
A return to zero revenue demonstrates the company remains pre‑commercial and dependent on clinical outcomes and financing. Without sustainable product sales, long‑term viability hinges on approvals or consistent external funding, increasing execution and financing risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Zero reported debt and materially improved equity provide durable financial flexibility for a clinical‑stage biotech. This reduces near‑term refinancing pressure, supports milestone funding for trials, and lowers bankruptcy risk compared with highly levered peers over the next 2–6 months.
Read all positive factors
Palvella Therapeutics (PVLA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.61B
Dividend YieldN/A
Average Volume (3M)357.59K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.03
Shares Outstanding13,676,490
10 Day Avg. Volume287,211
30 Day Avg. Volume357,591
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-2.46
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-70.36
Forecast
1Y Price Target
$219.04Price Target Upside81.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.88
Revenue Forecast (FY)$226.67K
Palvella Therapeutics Business Overview & Revenue Model
Company Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydr...
How the Company Makes Money
Palvella Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company aims to achieve profitability by obtaining regulatory approvals for its therapies and subsequently mark...
Palvella Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 25.90M | 31.42M | 29.32M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 23.12M | 29.05M | 29.32M |
| EBITDA | -19.11M | -13.12M | 18.69M | -30.50M | -43.37M | -34.94M |
| Net Income | -32.95M | -17.43M | 18.69M | -33.28M | -45.74M | -37.23M |
Balance Sheet | ||||||
| Total Assets | 66.94M | 88.23M | 7.55M | 16.52M | 153.56M | 105.01M |
| Cash, Cash Equivalents and Short-Term Investments | 63.57M | 83.60M | 7.35M | 16.05M | 117.76M | 70.44M |
| Total Debt | 16.02M | 0.00 | 0.00 | 0.00 | 14.89M | 16.96M |
| Total Liabilities | 28.25M | 25.63M | 11.43M | 39.70M | 102.81M | 73.98M |
| Stockholders Equity | 38.68M | 62.61M | -3.88M | -23.17M | 50.76M | 31.03M |
Cash Flow | ||||||
| Free Cash Flow | -25.47M | -10.84M | -13.70M | -14.84M | -8.61M | -48.62M |
| Operating Cash Flow | -25.47M | -10.84M | -13.70M | -14.84M | -7.66M | -45.90M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -949.00K | 39.21M |
| Financing Cash Flow | 74.17M | 87.09M | 5.00M | 9.57M | 59.13M | 10.12M |
Palvella Therapeutics Technical Analysis
Neutral
120.39
Price Trends
104.83
Positive
98.89
Positive
73.25
Positive
Market Momentum
2.52
Positive
50.40
Neutral
31.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PVLA, the sentiment is Neutral. The current price of 120.39 is below the 20-day moving average (MA) of 126.99, above the 50-day MA of 104.83, and above the 200-day MA of 73.25, indicating a neutral trend. The MACD of 2.52 indicates Positive momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 31.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PVLA.
Palvella Therapeutics Risk Analysis
Palvella Therapeutics disclosed 55 risk factors in its most recent earnings report. Palvella Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palvella Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $782.18M | 8.89 | 14.69% | ― | 27.12% | ― | |
58 Neutral | $2.05B | -13.06 | -34.75% | ― | ― | -17.01% | |
53 Neutral | $364.60M | -42.31 | -25.72% | ― | ― | -73.48% | |
52 Neutral | $5.65B | -6.99 | -29.95% | ― | ― | 12.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.61B | -15.28 | -64.41% | ― | ― | ― | |
47 Neutral | $1.60B | -5.54 | -57.51% | ― | 48.32% | -1.91% |
* Healthcare Sector Average
PVLA
Palvella Therapeutics
117.61
89.85
323.67%
TBPH
Theravance Biopharma
15.19
5.88
63.16%
MNPR
Monopar Therapeutics Inc
54.56
13.17
31.82%
NRIX
Nurix Therapeutics
15.53
2.98
23.75%
TERN
Terns Pharmaceuticals
53.17
50.05
1604.17%
TYRA
Tyra Bioscience
38.03
28.37
293.69%
Palvella Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Palvella Highlights QTORIN Rapamycin Progress in New Presentation
Positive
Jan 29, 2026
On January 29, 2026, Palvella Therapeutics posted a new corporate presentation outlining progress on its late-stage pipeline and highlighting QTORIN 3.9% rapamycin anhydrous gel as a potential first FDA-approved, first-line standard-of-care therap...
Business Operations and StrategyProduct-Related Announcements
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook
Positive
Jan 12, 2026
On January 12, 2026, Palvella Therapeutics posted a new corporate presentation outlining the advancement of its late‑stage pipeline, led by QTORIN 3.9% rapamycin anhydrous gel, which it positions as a potential first FDA‑approved, firs...
Business Operations and StrategyProduct-Related Announcements
Palvella Therapeutics Reports Positive Phase 2 Study Results
Positive
Dec 15, 2025
On December 15, 2025, Palvella Therapeutics announced positive topline results from their Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations. The study achieved statistical significance on...
Business Operations and StrategyFinancial Disclosures
Palvella Therapeutics Reports Q3 2025 Financial Results
Positive
Nov 10, 2025
Palvella Therapeutics reported its third quarter 2025 financial results and provided a corporate update, highlighting the progress in its rare disease pipeline. The company is advancing its QTORIN rapamycin product candidates, with significant upc...
Business Operations and StrategyProduct-Related Announcements
Palvella Therapeutics Unveils QTORIN™ Pitavastatin for DSAP
Positive
Nov 5, 2025
On November 5, 2025, Palvella Therapeutics announced a new product candidate, QTORIN™ pitavastatin, designed to treat disseminated superficial actinic porokeratosis (DSAP). This announcement marks a significant step as it aims to introduce t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.